Recently, we and others have demonstrated that SMARCA4/2-deficient ovarian cancers rely on epigenetic reprogramming and are responsive to inhibitors targeting the polycomb repressive complex 2, histone deacetylases, and the bromodomain-containing protein 427–30. This evidence concerns the gene SMARCA4 and ovarian carcinoma.